UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 20, 2016
bluebird bio, Inc.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
001-35966 |
|
13-3680878 |
|
(State or other jurisdiction of |
|
(Commission |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
150 Second Street Cambridge, MA |
|
02141 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code (339) 499-9300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On April 20, 2016, bluebird bio, Inc. (“bluebird”) issued a press release announcing clinical data from its Starbeam clinical study of its Lenti-D product candidate, presented at the American Academy of Neurology (AAN) 2016 Annual Meeting in Vancouver, British Columbia, Canada on April 20, 2016. The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press release issued by bluebird bio, Inc. on April 20, 2016. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
bluebird bio, Inc. |
||
|
|
|
|
|
|
|
Date: April 20, 2016 |
|
By: |
|
/s/ Jason F. Cole |
|
|
|
|
|
Jason Cole |
|
|
|
|
|
Chief Legal Officer |
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press release issued by bluebird bio, Inc. on April 20, 2016. |